TN2013000215A1 - Substituted sodium-1h-pyrazole-5 -olate - Google Patents

Substituted sodium-1h-pyrazole-5 -olate

Info

Publication number: TN2013000215A1
Authority: TN; Tunisia
Prior art keywords: olate; pyrazole; diseases; substituted sodium; treating
Prior art date: 2010-11-18

Application number

TNP2013000215A

Other languages

English (en)

Inventor

Jorg Gries

Stefan Koep

Hans Christian Militzer

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-18

Filing date

2013-05-17

Publication date

2014-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000215(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-17 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-11-10 Publication of TN2013000215A1 publication Critical patent/TN2013000215A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

TNP2013000215A 2010-11-18 2013-05-17 Substituted sodium-1h-pyrazole-5 -olate TN2013000215A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102010044131A DE102010044131A1 (de)	2010-11-18	2010-11-18	Substituiertes Natrium-1H-pyrazol-5-olat
PCT/EP2011/070099 WO2012065967A1 (fr)	2010-11-18	2011-11-15	Sel de sodium de 1h-pyrazol-5-olate substitué

Publications (1)

Publication Number	Publication Date
TN2013000215A1 true TN2013000215A1 (en)	2014-11-10

Family

ID=44999768

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000215A TN2013000215A1 (en)	2010-11-18	2013-05-17	Substituted sodium-1h-pyrazole-5 -olate

Country Status (46)

Country	Link
US (2)	US8653074B2 (fr)
EP (1)	EP2640718B8 (fr)
JP (1)	JP5918779B2 (fr)
KR (2)	KR20180023043A (fr)
CN (2)	CN103270031B (fr)
AP (1)	AP3429A (fr)
AR (1)	AR083887A1 (fr)
AU (1)	AU2011331305B2 (fr)
BR (1)	BR112013012223B1 (fr)
CA (1)	CA2818002C (fr)
CL (1)	CL2013001390A1 (fr)
CO (1)	CO6741155A2 (fr)
CR (1)	CR20130196A (fr)
CU (1)	CU20130072A7 (fr)
CY (1)	CY1120375T1 (fr)
DE (1)	DE102010044131A1 (fr)
DK (1)	DK2640718T3 (fr)
DO (1)	DOP2013000096A (fr)
EA (1)	EA023103B1 (fr)
EC (1)	ECSP13012627A (fr)
ES (1)	ES2675580T3 (fr)
GT (1)	GT201300125A (fr)
HK (1)	HK1210776A1 (fr)
HR (1)	HRP20180993T1 (fr)
HU (1)	HUE038024T2 (fr)
IL (1)	IL226192A (fr)
JO (1)	JOP20110347B1 (fr)
LT (1)	LT2640718T (fr)
MA (1)	MA34671B1 (fr)
MX (1)	MX347670B (fr)
MY (1)	MY167219A (fr)
NZ (1)	NZ610614A (fr)
PE (2)	PE20180324A1 (fr)
PH (1)	PH12013500997A1 (fr)
PL (1)	PL2640718T3 (fr)
PT (1)	PT2640718T (fr)
RS (1)	RS57599B1 (fr)
SG (1)	SG189975A1 (fr)
SI (1)	SI2640718T1 (fr)
TN (1)	TN2013000215A1 (fr)
TR (1)	TR201806652T4 (fr)
TW (1)	TWI516485B (fr)
UA (1)	UA112422C2 (fr)
UY (1)	UY33736A (fr)
WO (1)	WO2012065967A1 (fr)
ZA (1)	ZA201304430B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102006050516A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) *	2010-11-18	2012-05-24	Bayer Schering Pharma Aktiengesellschaft	Substituiertes Natrium-1H-pyrazol-5-olat
CA2872726C (fr) *	2012-05-08	2020-07-07	Hans-Christian Militzer	Procede de production de composes triazole
WO2015055564A1 (fr) *	2013-10-17	2015-04-23	Bayer Pharma Aktiengesellschaft	Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate
EP3569232A1 (fr)	2014-09-26	2019-11-20	The Cleveland Clinic Foundation	Traitement et prévention d'une maladie avec agents de réduction de tma et tmao
CL2015003047A1 (es) *	2015-10-15	2016-06-17	Univ Chile	Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
WO2018149929A1 (fr) *	2017-02-16	2018-08-23	Bayer Pharma Aktiengesellschaft	Dosages de gènes rapporteurs et analyse transcriptionnelle combinés
EP3888684A1 (fr) *	2020-03-31	2021-10-06	Bayer Animal Health GmbH	Composition ayant une acceptation volontaire améliorée

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1519069A (fr)	1966-04-13	1968-03-29	Geigy Ag J R	Dérivés du sulfanilamide et leur préparation
US4075003A (en)	1975-12-11	1978-02-21	Eli Lilly And Company	Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en)	1975-12-11	1979-09-11	Lilly Co Eli	Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl)	1976-09-20	1979-06-30	Lilly Co Eli	Srodek chwastobojczy
US4663327A (en)	1984-05-23	1987-05-05	Bayer Aktiengesellschaft	1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de)	1984-11-28	1986-05-28	Bayer Ag, 5090 Leverkusen	1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de)	1985-07-30	1987-02-12	Bayer Ag	1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de)	1992-02-19	1993-08-26	Bayer Ag	Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
JPH0735361B2 (ja) *	1993-09-09	1995-04-19	日産化学工業株式会社	ヒドラゾン誘導体およびその製造方法
FR2725988B1 (fr)	1994-10-24	1997-01-24	Roussel Uclaf	Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja)	1997-05-07	1998-11-17	Daiichi Rajio Isotope Kenkyusho:Kk	ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de)	1999-03-03	2000-09-07	Merck Patent Gmbh	Pyrazol-3-on-derivate
US6878729B2 (en)	2001-05-04	2005-04-12	The Procter & Gamble Company	Medicinal uses of dihydropyrazoles
AU2002308732A1 (en)	2001-05-15	2002-11-25	Ortho-Mcneil Pharmaceutical, Inc.	Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
CA2446864C (fr)	2001-05-16	2011-02-15	Vertex Pharmaceuticals Incorporated	Inhibiteurs de src et autres proteine kinases
MXPA04002583A (es)	2001-09-21	2004-06-18	Solvay Pharm Bv	Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
AU2002359714B2 (en)	2001-12-18	2006-12-21	Merck Sharp & Dohme Corp.	Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en)	2002-03-01	2004-09-09	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
UY27813A1 (es) *	2002-05-31	2003-12-31	Smithkline Beecham Corp	Inhibidores de la peptido-desformilasa
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
US7652033B2 (en)	2003-03-27	2010-01-26	Emory University	HIF-1 inhibitors
AU2004228057A1 (en)	2003-04-03	2004-10-21	Merck & Co., Inc.	Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en)	2003-05-01	2004-11-18	Panacea Pharmaceuticals, Inc.	Methods of treating ischemic related conditions
EP1646382A4 (fr)	2003-06-30	2010-07-21	Hif Bio Inc	Composes, compositions et procedes
CN1842332A (zh) *	2003-06-30	2006-10-04	Hif生物公司	化合物、组合物及方法
EP1768687A2 (fr)	2004-06-29	2007-04-04	Massachusetts Institute Of Technology	Procedes et compositions concernant la modulation de jonctions intercellulaires
DE102008020113A1 (de)	2008-04-23	2009-10-29	Bayer Schering Pharma Aktiengesellschaft	Substituierte Dihydropyrazolone und ihre Verwendung
WO2006101903A1 (fr)	2005-03-16	2006-09-28	Aventis Pharmaceuticals Inc.	Dipyrazoles utiles comme agents du systeme nerveux central
DE102005019712A1 (de)	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (fr)	2005-07-08	2007-01-18	Kalypsys, Inc.	Modificateurs d'absorption de cholesterol cellulaire
WO2007121687A1 (fr)	2006-04-26	2007-11-01	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
DE102006050513A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de)	2010-11-18	2012-05-24	Bayer Schering Pharma Aktiengesellschaft	Substituiertes Natrium-1H-pyrazol-5-olat

2010
- 2010-11-18 DE DE102010044131A patent/DE102010044131A1/de not_active Withdrawn
2011
- 2011-11-08 US US13/291,271 patent/US8653074B2/en active Active
- 2011-11-15 ES ES11784992.7T patent/ES2675580T3/es active Active
- 2011-11-15 PH PH1/2013/500997A patent/PH12013500997A1/en unknown
- 2011-11-15 RS RS20180749A patent/RS57599B1/sr unknown
- 2011-11-15 UA UAA201307718A patent/UA112422C2/uk unknown
- 2011-11-15 CA CA2818002A patent/CA2818002C/fr active Active
- 2011-11-15 AR ARP110104269A patent/AR083887A1/es not_active Application Discontinuation
- 2011-11-15 PE PE2017002012A patent/PE20180324A1/es unknown
- 2011-11-15 PL PL11784992T patent/PL2640718T3/pl unknown
- 2011-11-15 MY MYPI2013700801A patent/MY167219A/en unknown
- 2011-11-15 CN CN201180055239.3A patent/CN103270031B/zh active Active
- 2011-11-15 KR KR1020187005194A patent/KR20180023043A/ko not_active Ceased
- 2011-11-15 HR HRP20180993TT patent/HRP20180993T1/hr unknown
- 2011-11-15 SG SG2013030887A patent/SG189975A1/en unknown
- 2011-11-15 NZ NZ610614A patent/NZ610614A/en unknown
- 2011-11-15 TR TR2018/06652T patent/TR201806652T4/tr unknown
- 2011-11-15 MA MA35911A patent/MA34671B1/fr unknown
- 2011-11-15 HU HUE11784992A patent/HUE038024T2/hu unknown
- 2011-11-15 PT PT117849927T patent/PT2640718T/pt unknown
- 2011-11-15 MX MX2013004797A patent/MX347670B/es active IP Right Grant
- 2011-11-15 PE PE2013000943A patent/PE20140391A1/es active IP Right Grant
- 2011-11-15 BR BR112013012223-4A patent/BR112013012223B1/pt active IP Right Grant
- 2011-11-15 KR KR1020137012680A patent/KR101984317B1/ko active Active
- 2011-11-15 LT LTEP11784992.7T patent/LT2640718T/lt unknown
- 2011-11-15 WO PCT/EP2011/070099 patent/WO2012065967A1/fr not_active Ceased
- 2011-11-15 AP AP2013006922A patent/AP3429A/xx active
- 2011-11-15 SI SI201131516T patent/SI2640718T1/en unknown
- 2011-11-15 EA EA201390703A patent/EA023103B1/ru not_active IP Right Cessation
- 2011-11-15 DK DK11784992.7T patent/DK2640718T3/da active
- 2011-11-15 CN CN201510059285.0A patent/CN104650047A/zh active Pending
- 2011-11-15 JP JP2013539223A patent/JP5918779B2/ja active Active
- 2011-11-15 AU AU2011331305A patent/AU2011331305B2/en active Active
- 2011-11-15 US US13/988,141 patent/US9533972B2/en active Active
- 2011-11-15 EP EP11784992.7A patent/EP2640718B8/fr active Active
- 2011-11-16 UY UY0001033736A patent/UY33736A/es active IP Right Grant
- 2011-11-17 TW TW100141958A patent/TWI516485B/zh active
- 2011-11-17 JO JOP/2011/0347A patent/JOP20110347B1/ar active
2013
- 2013-04-30 CO CO13109274A patent/CO6741155A2/es not_active Application Discontinuation
- 2013-05-02 CR CR20130196A patent/CR20130196A/es unknown
- 2013-05-03 DO DO2013000096A patent/DOP2013000096A/es unknown
- 2013-05-07 IL IL226192A patent/IL226192A/en active IP Right Grant
- 2013-05-15 GT GT201300125A patent/GT201300125A/es unknown
- 2013-05-16 CU CU2013000072A patent/CU20130072A7/es unknown
- 2013-05-16 EC ECSP13012627 patent/ECSP13012627A/es unknown
- 2013-05-16 CL CL2013001390A patent/CL2013001390A1/es unknown
- 2013-05-17 TN TNP2013000215A patent/TN2013000215A1/fr unknown
- 2013-06-14 ZA ZA2013/04430A patent/ZA201304430B/en unknown
2015
- 2015-11-23 HK HK15111529.0A patent/HK1210776A1/xx unknown
2018
- 2018-06-28 CY CY20181100675T patent/CY1120375T1/el unknown

Also Published As

Publication number	Publication date
MX2013004797A (es)	2013-06-28
DOP2013000096A (es)	2013-06-15
US8653074B2 (en)	2014-02-18
IL226192A0 (en)	2013-07-31
UA112422C2 (uk)	2016-09-12
JP5918779B2 (ja)	2016-05-18
PE20140391A1 (es)	2014-03-29
US20130310381A1 (en)	2013-11-21
HK1188782A1 (en)	2014-05-16
EA201390703A1 (ru)	2013-12-30
PH12013500997A1 (en)	2015-03-06
IL226192A (en)	2016-06-30
ECSP13012627A (es)	2013-07-31
TW201307328A (zh)	2013-02-16
JP2014500877A (ja)	2014-01-16
CA2818002C (fr)	2019-01-15
NZ610614A (en)	2015-05-29
MA34671B1 (fr)	2013-11-02
ZA201304430B (en)	2014-12-23
PT2640718T (pt)	2018-07-04
BR112013012223B1 (pt)	2021-06-29
CN104650047A (zh)	2015-05-27
ES2675580T3 (es)	2018-07-11
PL2640718T3 (pl)	2018-08-31
US9533972B2 (en)	2017-01-03
RS57599B1 (sr)	2018-11-30
CN103270031B (zh)	2015-06-17
AU2011331305A1 (en)	2013-06-06
KR20130131335A (ko)	2013-12-03
SI2640718T1 (en)	2018-08-31
CL2013001390A1 (es)	2014-04-04
CY1120375T1 (el)	2019-07-10
AR083887A1 (es)	2013-03-27
LT2640718T (lt)	2018-07-10
UY33736A (es)	2012-06-29
AU2011331305B2 (en)	2016-06-02
JOP20110347B1 (ar)	2021-08-17
TWI516485B (zh)	2016-01-11
CR20130196A (es)	2013-08-06
EP2640718B1 (fr)	2018-03-28
BR112013012223A2 (pt)	2020-03-10
AP2013006922A0 (en)	2013-06-30
KR101984317B1 (ko)	2019-05-30
EP2640718B8 (fr)	2018-06-27
MX347670B (es)	2017-05-03
WO2012065967A1 (fr)	2012-05-24
HUE038024T2 (hu)	2018-09-28
EP2640718A1 (fr)	2013-09-25
EA023103B1 (ru)	2016-04-29
CN103270031A (zh)	2013-08-28
CU20130072A7 (es)	2013-09-27
HRP20180993T1 (hr)	2018-08-10
TR201806652T4 (tr)	2018-06-21
SG189975A1 (en)	2013-06-28
MY167219A (en)	2018-08-14
CO6741155A2 (es)	2013-08-30
PE20180324A1 (es)	2018-02-13
AP3429A (en)	2015-09-30
CA2818002A1 (fr)	2012-05-24
GT201300125A (es)	2017-07-26
DE102010044131A1 (de)	2012-05-24
HK1210776A1 (en)	2016-05-06
KR20180023043A (ko)	2018-03-06
US20120129857A1 (en)	2012-05-24
DK2640718T3 (da)	2018-07-16

Publication	Publication Date	Title
TN2013000215A1 (en)	2014-11-10	Substituted sodium-1h-pyrazole-5 -olate
MX2010006143A (es)	2010-07-06	Azolilmetiloxiranos, su uso y agentes que lo contienen.
TN2009000132A1 (en)	2010-10-18	Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
PH12013500333A1 (en)	2013-04-22	Antibodies for epidermal growth factor receptor 3 (her3)
SG10201407281UA (en)	2014-12-30	Specific binding proteins and uses thereof
MX2012005111A (es)	2012-05-22	Estructuras fibrosas y metodos para elaborarlas.
WO2008060374A3 (fr)	2008-11-27	Procédés et compositions utiles pour une cicatrisation de plaie chez les diabétiques
MX2010006396A (es)	2010-07-05	Anticuerpos bivalentes, biespecificos.
MX2010005682A (es)	2010-06-22	Anticuerpos bivalentes, biespecificos.
MX2010005888A (es)	2010-06-22	Anticuerpos bivalentes biespecificos.
MY172372A (en)	2019-11-21	Compositions and methods for lowering triglycerides
TN2012000366A1 (en)	2014-01-30	Anticoagulant antidotes
AU2011328009A8 (en)	2013-08-01	Compounds and methods for treating pain
MX2010008060A (es)	2010-08-10	Anticuerpos humanizados especificos para el factor von willerbrand.
MX348886B (es)	2017-07-03	Estructuras fibrosas y métodos para fabricarlas.
WO2008046581A3 (fr)	2008-06-12	Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
IN2012DN00797A (fr)	2015-06-26
IL236081A (en)	2017-11-30	METHOD FOR PRODUCING 4- [5- (pyridine-4-ram) -1,2,4- h1- triazole-3-ram] pyridine-2-carbonitrile and intermediate phase thereof
PH12015502405B1 (en)	2016-02-22	Methods and compositions for wound healing
MA33290B1 (fr)	2012-05-02	Pipéridines substituées
WO2009115252A3 (fr)	2010-03-25	Pyrazolamides substitués et leur utilisation
MY183041A (en)	2021-02-08	Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
MA33291B1 (fr)	2012-05-02	Pipéridines substituées
MX2013006867A (es)	2013-07-05	Procedimiento para la preparacion de sales de cis-1-amonio-4-alcoxiciclohexanocarbonitrilo.
WO2012082942A3 (fr)	2012-10-26	Analogues de neuropeptides, compositions et procédés pour le traitement de la douleur